Bridgewater Associates LP Buys New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bridgewater Associates LP acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 2nd quarter, Holdings Channel reports. The firm acquired 241,669 shares of the company’s stock, valued at approximately $2,393,000.

Other hedge funds have also bought and sold shares of the company. Legal & General Group Plc increased its holdings in shares of Teva Pharmaceutical Industries by 83.8% in the 2nd quarter. Legal & General Group Plc now owns 8,728,662 shares of the company’s stock valued at $86,413,000 after acquiring an additional 3,980,002 shares during the last quarter. Camber Capital Management LP boosted its position in Teva Pharmaceutical Industries by 22.2% during the 1st quarter. Camber Capital Management LP now owns 5,500,000 shares of the company’s stock worth $63,470,000 after acquiring an additional 1,000,000 shares during the period. Psagot Investment House Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Psagot Investment House Ltd. now owns 5,312,487 shares of the company’s stock worth $61,306,000 after buying an additional 385,583 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 10.3% in the 2nd quarter. Geode Capital Management LLC now owns 5,187,569 shares of the company’s stock worth $51,158,000 after buying an additional 486,108 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Teva Pharmaceutical Industries by 8.1% in the 2nd quarter. Swiss National Bank now owns 4,668,293 shares of the company’s stock worth $46,216,000 after buying an additional 347,894 shares in the last quarter. Institutional investors own 51.08% of the company’s stock.

In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 50,860 shares of the company’s stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $9.95, for a total value of $506,057.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.74% of the stock is owned by corporate insiders.

NYSE:TEVA opened at $9.81 on Thursday. The firm has a market capitalization of $10.82 billion, a price-to-earnings ratio of -2.75, a PEG ratio of 1.00 and a beta of 1.44. Teva Pharmaceutical Industries Limited has a 1-year low of $8.24 and a 1-year high of $13.30. The company has a current ratio of 1.01, a quick ratio of 0.67 and a debt-to-equity ratio of 1.91. The business’s fifty day moving average price is $9.50 and its 200 day moving average price is $10.00.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 28th. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $4.03 billion. Teva Pharmaceutical Industries had a positive return on equity of 23.88% and a negative net margin of 23.98%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.51 earnings per share for the current year.

A number of equities research analysts have recently issued reports on TEVA shares. Raymond James cut their target price on Teva Pharmaceutical Industries from $15.00 to $14.00 and set an “outperform” rating on the stock in a research report on Thursday, July 29th. Wells Fargo & Company cut their target price on Teva Pharmaceutical Industries from $12.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 29th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $11.13.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets.

Further Reading: Why is cost of goods sold important?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.